1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1002/cmdc.201100559" target="_blank" rel="noreferrer noopener">http://doi.org/10.1002/cmdc.201100559</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
375-384
Issue
3
Volume
7
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Polycyclic Cage Structures As Lipophilic Scaffolds For Neuroactive Drugs
Publisher
An entity responsible for making the resource available
Chemmedchem
Date
A point or period of time associated with an event in the lifecycle of the resource
2012
2012-03
Subject
The topic of the resource
Alzheimer's disease; apoptosis; benzodiazepine-receptors; biological activity; cage compounds; calcium-antagonists; carbonic-anhydrase inhibitors; d-aspartate receptor; drug design; fluorescent ligands; monoamine-oxidase-b; neuroprotection; nitric-oxide; parkinsons-disease; Pharmacology & Pharmacy; sigma-receptors
Creator
An entity primarily responsible for making the resource
Joubert J; Geldenhuys W J; Van der Schyf C J; Oliver D W; Kruger H G; Govender T; Malan S F
Description
An account of the resource
Polycyclic cage scaffolds have been successfully used in the development of numerous lead compounds demonstrating activity in the central nervous system (CNS). Several neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, Huntingtons disease, schizophrenia, and stroke, as well as drug abuse, can be modulated with polycyclic cage derivatives. These cage moieties, including adamantane and pentacycloundecane derivatives, improve the pharmacokinetic and pharmacodynamic properties of conjugated parent drugs and serve as an important scaffold in the design of therapeutically active agents for the treatment of neurological disorders. In this Minireview, we focus on the recent developments in the field of polycyclic cage compounds, as well as the relationship between the lipophilic character of these cage-derived drugs and the ability of such compounds to target and reach the CNS and improve the pharmacodynamic properties of compounds conjugated to it.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/cmdc.201100559" target="_blank" rel="noreferrer noopener">10.1002/cmdc.201100559</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
2012
Alzheimer's disease
Apoptosis
benzodiazepine-receptors
biological activity
cage compounds
calcium-antagonists
carbonic-anhydrase inhibitors
Chemmedchem
d-aspartate receptor
Drug Design
fluorescent ligands
Geldenhuys W J
Govender T
Joubert J
Journal Article or Conference Abstract Publication
Kruger H G
Malan S F
monoamine-oxidase-b
Neuroprotection
nitric-oxide
Oliver D W
parkinsons-disease
Pharmacology & Pharmacy
sigma-receptors
Van der Schyf C J